As per MRFR analysis, the US Carrier Screening Market Size was estimated at 1.37 (USD Billion) in 2023. The US Carrier Screening Market Industry is expected to grow from 1.49(USD Billion) in 2024 to 3.79 (USD Billion) by 2035. The US Carrier Screening Market CAGR (growth rate) is expected to be around 8.84% during the forecast period (2025 - 2035).
The US Carrier Screening Market is experiencing growth driven by several key market drivers, including the increasing prevalence of genetic disorders and a rising awareness among healthcare professionals and patients regarding the importance of genetic testing. With advancements in technology, such as next-generation sequencing, testing has become faster and more accessible.
Many states in the US are pushing for expanded carrier screening as part of standard prenatal care, leading to a significant shift in acceptance among both providers and patients. There are opportunities to be explored in the area of personalized medicine. As healthcare focuses more on individualized treatment plans, the demand for carrier screening will likely increase, enabling better-informed reproductive choices.
Additionally, educational programs aimed at increasing public knowledge of genetic disorders can help foster an environment where carrier screening is seen as a normal part of healthcare. Recent trends indicate a growing emphasis on integrating carrier screening into routine healthcare protocols. The rise of telehealth services has also made it easier for patients to consult with genetic counselors, facilitating discussions about carrier screening.
The health insurance landscape is evolving, with more policies beginning to cover genetic testing, which further supports access to these services. As the regulatory framework in the US adjusts to accommodate new technologies and practices, the Carrier Screening Market is poised for further development, leveraging these trends to enhance patient care and service availability.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising awareness regarding genetic disorders and the benefits of carrier screening in preventing genetically transmitted diseases is one of the significant drivers for the US Carrier Screening Market Industry. According to the US Centers for Disease Control and Prevention (CDC), about 1 in 33 babies is born with a birth defect.
With such alarming statistics, health campaigns and educational programs led by organizations like the American College of Obstetricians and Gynecologists (ACOG) have been instrumental in emphasizing the importance of screening. Furthermore, the increase in awareness is prompting more parents to seek genetic testing before or during pregnancy, thus stimulating the growth of the market. As technology advances, screening processes are becoming more accessible, integrated into routine check-ups, and affordable, providing a robust growth trajectory for the US Carrier Screening Market Industry in the coming years.
Technological innovations in genetic testing methods such as Next Generation Sequencing (NGS) and improvements in bioinformatics tools are significant drivers for the US Carrier Screening Market Industry. The advent of these technologies has dramatically reduced the costs and time associated with genetic testing.
According to the National Institutes of Health (NIH), the cost of sequencing a human genome has dropped from approximately $100 million in 2001 to about $1,000 today. Leading companies like Illumina and Thermo Fisher Scientific have been at the forefront of these advancements, ensuring that carrier screening becomes increasingly reliable and widespread. This continued innovation will directly boost the adoption rates of carrier screening in the United States.
The increasing shift towards personalized medicine is propelling the demand for carrier screening in the US Carrier Screening Market Industry. As healthcare moves towards more individualized treatment plans, understanding a patient's genetic makeup becomes essential.
A report from the National Institutes of Health reveals that more than 80 percent of chronic diseases have a genetic component, underscoring the demand for personalized approaches. Organizations such as the FDA are encouraging this movement by approving drugs and therapies based on genetic profiles. Therefore, as more healthcare providers integrate personalized medicine into their practices, the need for genetic carrier screening is expected to surge, significantly impacting the growth of the market.
Government initiatives aimed at improving maternal and child health through genetic testing significantly influence the US Carrier Screening Market Industry's growth. Federal programs under the Maternal and Child Health Bureau are promoting awareness and access to carrier screening, enhancing the number of individuals who opt for genetic tests.
According to the Health Resources and Services Administration (HRSA), investments in public health initiatives have increased funding by over 15% in the last five years for genetic screening. These policies not only enhance the field's reputation and legitimacy but also encourage more healthcare professionals to recommend screening. With continued governmental support, the accessibility and awareness of carrier screening are likely to expand, driving further market growth.
The Test Type segment of the US Carrier Screening Market provides critical insights into the various methodologies employed for genetic testing. This market segment is essential as it enables healthcare professionals to identify potential carriers of genetic disorders and assess the risk of passing these conditions to offspring.
The US regulatory environment is evolving to keep pace with these advancements, ensuring that testing remains safe, effective, and accessible. Each of these Test Type categories contributes significantly to the growth and development of the US Carrier Screening Market, addressing an increasing need for advanced genetic insights among the population. The growing acceptance of carrier screening as a standard practice in reproductive planning illustrates the market's evolution and its increasing relevance in healthcare, particularly in the US. The US Carrier Screening Market continues to thrive on the basis of these diverse testing methodologies, ensuring that individuals have access to crucial genetic information that can shape their family planning choices.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Technology segment of the US Carrier Screening Market encompasses several advanced methodologies that are essential for genetic analysis and screening processes. Among these, Next Generation Sequencing (NGS) stands out as a powerful tool that allows for comprehensive analysis of genetic information, thus significantly enhancing the accuracy of carrier screening.
The increasing prevalence of genetic disorders in the US has driven demand for these technologies, as healthcare providers emphasize early detection and prevention. Additionally, advancements in technology and growing awareness of carrier screening's importance among patients are accelerating the adoption of these testing methods. This market segment is characterized by rapid developments and innovations aimed at improving accuracy and turnaround times, reflecting the overarching trends towards personalized medicine and targeted therapies. As such, the Technology segment plays a pivotal role in the overall landscape of the US Carrier Screening Market, offering critical solutions to meet the needs of both healthcare providers and patients.
The Application segment of the US Carrier Screening Market plays a crucial role in identifying genetic disorders prevalent in various populations. This sector comprises different screening approaches, including Prenatal Screening, Preconception Screening, and Newborn Screening.
Overall, the US Carrier Screening Market segmentation reflects growing awareness and adoption of genetic screening as a preventive healthcare measure, driven by advancements in technology, a focus on personalized medicine, and the increasing prevalence of genetic disorders. As the market evolves, regulatory support and public education will also play essential roles in expanding the reach and acceptance of these applications, ultimately benefiting families and healthcare providers across the United States.
The US Carrier Screening Market encompasses various end users including Hospitals, Diagnostic Laboratories, and Research Institutions, each playing a critical role in the industry. Hospitals are significant players in this segment as they provide comprehensive healthcare services, integrating carrier screening into routine genetic testing for patient management and counseling.
Diagnostic Laboratories are equally vital, specializing in genetic tests that help in identifying carrier status for inherited conditions, thus supporting physicians and patients with precise information for decision-making. Research Institutions contribute essential advancements in the field by conducting studies that enhance the understanding of genetic disorders and the development of new testing methodologies. The growing awareness of genetic conditions and the importance of preconception screening are creating substantial opportunities within the market, driven by the need for personalized medicine and early intervention strategies. Moreover, federal and state initiatives backing genetic testing underscore the relevance of this market segment. Overall, the end user category of the US Carrier Screening Market is characterized by a collaborative approach aimed at improving public health through informed genetic insights.
The US Carrier Screening Market is a rapidly evolving segment within the broader healthcare landscape, driven by advancements in genetic testing technologies and increasing consumer awareness of genetic disorders. It serves a critical role in preconception planning and prenatal care, enabling prospective parents to understand their genetic makeup and potential risks for inherited conditions.
With the rise of personalized medicine and an emphasis on preventive healthcare, the demand for carrier screening tests has escalated. This has led to a competitive environment characterized by several key players that offer a range of tests, including single-gene tests and expanded carrier panels. Companies in this market leverage technology, partnerships, and innovative solutions to gain market share and provide comprehensive services to healthcare providers and patients alike.
LabCorp is a significant player in the US Carrier Screening Market, recognized for its broad testing capabilities and extensive experience in laboratory services. The company boasts a strong presence across the United States, with a network of laboratories and patient service centers that facilitate easy access to carrier screening tests.
LabCorp's strengths lie in its robust portfolio of genetic testing options and a commitment to high-quality laboratory standards. The company’s ability to integrate advanced testing technologies and its focus on delivering accurate results in a timely manner enhance its competitive edge. Furthermore, LabCorp continues to invest in research and development, aiming to expand its offerings and adapt to the evolving needs of healthcare providers and patients, solidifying its position as a trusted provider in the market.
Fulgent Genetics is another influential entity within the US Carrier Screening Market, known for its innovative approach to genetic testing. The company offers a comprehensive array of tests tailored to carrier screening, including expansive panels that assess multiple genetic conditions in a single test.
Fulgent Genetics has developed a reputation for its cutting-edge technology and quick turnaround times, which appeal to both healthcare practitioners and patients. The company’s strengths include its ability to customize testing solutions, ensuring that healthcare providers can obtain specific information relevant to their patient populations. Fulgent Genetics has also engaged in strategic mergers and acquisitions to enhance its market presence and broaden its product offerings. This dynamic approach, combined with a focus on improving the accessibility and affordability of genetic testing, has bolstered its standing within the US Carrier Screening Market, making it a notable competitor.
The US Carrier Screening Market is currently experiencing significant developments and growth, largely driven by advancements in genetic testing technologies and rising consumer awareness. Recent activities include LabCorp's continued expansion of its genetic testing services, as they emphasize personalized medicine.
Myriad Genetics has also enhanced its portfolio, focusing on hereditary cancer testing alongside carrier screening, which reinforces their commitment to comprehensive patient care. Moreover, in September 2023, Fulgent Genetics announced an acquisition of a specialty laboratory specializing in reproductive health to broaden its carrier screening offerings. The merger activity signals a trend towards consolidation, aiming to leverage complementary technologies and improve market positioning.
Additionally, Quest Diagnostics has increased its investments in digital health solutions, enhancing access to carrier screening tests for patients. Overall, the market is witnessing a market valuation growth in companies like Invitae and Color Genomics due to increased demand for genetic insights and preventative healthcare. In the past two years, noteworthy developments have included the introduction of expanded carrier screening panels, reflecting an ongoing trend towards more inclusive testing methodologies.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.37(USD Billion) |
| MARKET SIZE 2024 | 1.49(USD Billion) |
| MARKET SIZE 2035 | 3.79(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.84% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | LabCorp, Fulgent Genetics, Myriad Genetics, PathGroup, Color Genomics, Healthlynked, Sema4, Veracyte, Invitae, Quest Diagnostics, Ambry Genetics, 23andMe, Sonora Quest Laboratories, GeneDx, Natera |
| SEGMENTS COVERED | Test Type, Technology, Application, End User |
| KEY MARKET OPPORTUNITIES | Increased demand for genetic counseling, Rising awareness of hereditary diseases, Expansion of at-home testing kits, Advancements in sequencing technologies, Integration with fertility treatments |
| KEY MARKET DYNAMICS | increasing awareness of genetic disorders, rise in health insurance coverage, advancements in genetic testing technology, growing demand for personalized medicine, government initiatives for preventive healthcare |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Carrier Screening Market is expected to be valued at 1.49 USD Billion in 2024.
By 2035, the US Carrier Screening Market is projected to reach a value of 3.79 USD Billion.
The expected CAGR for the US Carrier Screening Market from 2025 to 2035 is 8.84%.
The market includes Single Gene Testing, Panel Testing, and Expanded Carrier Screening.
The Single Gene Testing segment is valued at 0.45 USD Billion in 2024.
The Panel Testing segment is projected to be valued at 1.0 USD Billion by 2035.
Expanded Carrier Screening is valued at 0.64 USD Billion in 2024.
Key players in the market include LabCorp, Myriad Genetics, Invitae, and Quest Diagnostics among others.
Increasing awareness about genetic disorders and advancements in technology are driving growth opportunities.
Regulatory hurdles and the complexity of genetic testing can pose challenges to market growth.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
